TF and neoplasm: For Bicluster 2, the observed alterations in methylation and expression suggest that eradication of tumor cells lead to a relative increase in non‐tumor cells (e.g., immune cells) in the tumors that respond well to treatment, which in turn is reflected in the loss of methylation at enhancers carrying TF binding regions of TFs related to immune development and increase in expression of immune‐related genes.